Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
A phase 2 trial of Pembrolizumab in metastatic cancer and biliary tract cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) is a phase 2 interventional study registered as NCT02628067 by Merck Sharp & Dohme LLC, with 1609 participants planned, started 2015-12-18 and due to reach its primary completion in 2027-05-04. Interventions recorded: pembrolizumab, pembrolizumab. Conditions listed: Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialBC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialGYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
Shares Endometrial cancer, Merck & Co. (MSD), Cervical cancer, Pembrolizumab.
- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialDose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Cervical cancer.